Lilly’s Rettrutide shows significant improvements in weight loss and blood sugarWSJ
Eli Lilly’s next-generation obesity drug retatrutide clears first late-stage diabetes trialcnbc
Study finds record weight loss from Lilly’s experimental diabetes shotbloomberg.com
Lilly’s triple agonist, retreptide, demonstrated significant reductions in A1C and weight in the first phase 3 trial for the treatment of type 2 diabetes.Eli Lilly
Eli Lilly’s ‘Triple-G’ drug causes significant blood sugar, weight reductions in diabetes trialstatnews.com
